Publication details

Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Omicron-dominant circulation: I-MOVE- COVID-19 and VEBIS SARI VE networks, Europe, 2021 to 2022

Authors

ANGELA MC Rose NICOLAY Nathalie MARTIN Virginia Sandonis MAZAGATOS Clara PETROVIC Goranka BARUCH Joaquin DENAYER Sarah SEYLER Lucie DOMEGAN Lisa LAUNAY Odile MACHADO Ausenda BURGUI Cristina VAIKUTYTE Roberta NIESSEN F Annabel LOGHIN Isabela I HUSA Petr AOUALI Nassera PANAGIOTAKOPOULOS George TOLKSDORF Kristin HORVATH Judit Krisztina HOWARD Jennifer POZO Francisco GALLARDO Virtudes NONKOVIC Diana DZIUGYTE Ausra BOSSUYT Nathalie DEMUYSER Thomas DUFFY Roisin NGUYEN Liem binh Luong KISLAYA Irina MARTINEZ-BAZ Ivan GEFENAITE Giedre KNOL Mirjam J POPESCU Corneliu SOUČKOVÁ Lenka SIMON Marc MICHELAKI Stella REICHE Janine FERENCZI Annamaria DELGADO-SANZ Concepcion MAKARIC Zvjezdana Lovric CAUCHI John Paul BARBEZANGE Cyril ELS Van Nedervelde DONNELL Joan DURIER Christine GUIOMAR Raquel CASTILLA Jesus JONIKAITE Indre BRUIJNING-VERHAGEN Patricia C J L LAZAR Mihaela DEMLOVÁ Regina WIRTZ Gil AMERALI Marina DUERRWALD Ralf KUNSTAR Mihaly Pal KISSLING Esther BACCI Sabrina VALENCIANO Marta KARABUVA Svjetlana MLADINOV Suzana MARKIC Johko PETRIC Petra Tomah TABAIN Irena ILIC Maja MLINARIC Ivan SMOLJO Petra NOVOSEL Iva Pem MELILLO Tanya BORG Maria-Louise LISSOIR Benedicte HOLEMANS Xavier HAINAUT Marc DAUBY Nicolas DELAERE Benedicte BOURGEOIS Marc PETIT Evelyn REYNDERS Marijke JOUCK Door MAGERMAN Koen BLEYEN Marieke VERMEULEN Melissa FIERENS Sebastien DUFRASNE Francois DAELEMANS Siel KERWI Ala'a Al BERTHET Francoise FAGHERAZZI Guy ALEXANDRE Myriam BENNETT Charlene CHRISTLE Jim CONNELL Jeff DORAN Peter FEENEY Laura MAHARJAN Binita MCDERMOTT Sinead MCNAMARA Rosa NURDIN Nadra LESIEUR Zineb CISSE Salif Mamadou HONNEUR Anne-Sophie DUVAL Xavier COSTA Yolande NADHIRA Fidouh GALTIER Florence CRANTELLE Laura FOULONGNE Vincent VANHEMS Phillipe AMOUR Selilah LINA Bruno LAINE Fabrice GALLAIS Laetitia LAGATHU Gisele MAISA Anna BERNARD-STOECKLIN Sibylle SAIDI Yacine BAUER Rebecca RODRIGUES Ana Paula SILVA Adriana GOMEZ Veronica TAVARES Margarida PEREIRA Debora MANATA Maria Jose GRUNER Heidi ALMEIDA Andre PINTO Paula BARBARA Cristina MIQUELEIZ Ana NAVASCUES Ana TROBAJO-SANMARTIN Camino EZPELETA Carmen EGUEES Nerea CENOZ Manuel Garcia ARDANAZ Eva GUEVARA Marcela MORENO-IRIBAS Conchi CASADO Itziar MICKIENE Aukse KULIESE Monika ORLIKOVA Hana DOROBAT Carmen Mihaela MANCIUC Carmen FLORESCU Simin Aysel MARIN Alexandru DINU Sorin PASCU Catalina IVANCIUC Alina BISTRICEANU Iulia OPREA Mihaela MIHAI Maria Elena BUDA Silke PREUSS Ute WEDDE Marianne OROSZI Beatrix KRISZTALOVICS Katalin TURI Gergo KRISTOF Katalin VARGA Csaba LI Ruoran MOREN Alain NARDONE Anthony

Year of publication 2023
Type Article in Periodical
Magazine / Source EUROSURVEILLANCE
MU Faculty or unit

Faculty of Medicine

Citation
Web https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2023.28.47.2300187
Doi http://dx.doi.org/10.2807/1560-7917.ES.2023.28.47.2300187
Keywords COVID-19; Europe; hospital; omicron; SARS-CoV-2; vaccine effectiveness
Description Introduction: The I-MOVE-COVID-19 and VEBIS hospital networks have been measuring COVID-19 vaccine effectiveness (VE) in participating European countries since early 2021. Aim: We aimed to measure VE against PCR-confirmed SARS-CoV-2 in patients >= 20 years hospitalised with severe acute respiratory infection (SARI) from December 2021 to July 2022 (Omicron-dominant period). Methods: In both networks, 46 hospitals (13 countries) follow a similar test-negative case-control protocol. We defined complete primary series vaccination (PSV) and first booster dose vaccination as last dose of either vaccine received >= 14 days before symptom onset (stratifying first booster into received < 150 and >= 150 days after last PSV dose). We measured VE overall, by vaccine category/product, age group and time since first mRNA booster dose, adjusting by site as a fixed effect, and by swab date, age, sex, and presence/absence of at least one commonly collected chronic condition. Results: We included 2,779 cases and 2,362 controls. The VE of all vaccine products combined against hospitalisation for laboratory-confirmed SARS-CoV-2 was 43% (95% CI: 29-54) for complete PSV (with last dose received >= 150 days before onset), while it was 59% (95% CI: 51-66) after addition of one booster dose. The VE was 85% (95% CI: 78-89), 70% (95% CI: 61-77) and 36% (95% CI: 17-51) for those with onset 14-59 days, 60-119 days and 120-179 days after booster vaccination, respectively. Conclusions: Our results suggest that, during the Omicron period, observed VE against SARI hospitalisation improved with first mRNA booster dose, particularly for those having symptom onset < 120 days after first booster dose.

You are running an old browser version. We recommend updating your browser to its latest version.

More info